Oral asthma drug KT-621 tested for Long-Term safety

NCT ID NCT07677059

Recruiting now Disease control Sponsor: Kymera Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study looks at the long-term safety and effectiveness of an oral drug called KT-621 in people with asthma. Participants have already completed a previous KT-621 asthma study. The goal is to see how well the drug works over time and if any side effects appear with longer use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KT-621 (oral drug)
What this could lead to: If successful, this could show that KT-621 is a safe and effective long-term treatment option for controlling asthma.
What could go wrong: This is an extension study, not a new treatment test. It may reveal side effects that were not seen in the shorter parent study, and results may not apply to all asthma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA (DIAGNOSIS)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Kymera Investigative Site
RECRUITING

Tampa, Florida, 33607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.